Payment overview · 2025
General Payments
$3,174.33
129 reported records · 24 companies
Healthcare provider profile · identity verified
Naum Meyerovich, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · REGO PARK, NY · NPI 1790750859
Verified facts
What the public records show
CMS Open Payments records show Naum Meyerovich, M.D received $3,174.33 in general payments during 2025 across 129 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Ozempic, Rexulti, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 509 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 845 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 407 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 356 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 515 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $530.82 | 16.7% | 23 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $343.09 | 10.8% | 14 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $300.34 | 9.5% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $266.27 | 8.4% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $259.16 | 8.2% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $210.28 | 6.6% | 8 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $210.04 | 6.6% | 8 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $177.61 | 5.6% | 8 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $154.73 | 4.9% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $153.67 | 4.8% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $100.42 | 3.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.15 | 3.0% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $82.29 | 2.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.68 | 1.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $31.54 | 1.0% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $30.74 | 1.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.65 | 0.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.04 | 0.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.00 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.18 | 0.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.33 | 0.7% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.73 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.73 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.84 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,174.33 | 129 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $530.82 | 23 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $325.19 | 15 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $300.34 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $210.28 | 8 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $210.04 | 8 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $177.61 | 8 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $177.61 | 8 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $171.57 | 7 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $167.80 | 9 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $154.73 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $138.57 | 5 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $114.05 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $100.42 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $98.47 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $97.92 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $82.29 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $69.72 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $48.40 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $40.68 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.68 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $31.54 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Scientific Affairs, LLC | $30.74 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 509 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 131 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 845 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 356 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
509 | 107 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
845 | 134 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
407 | 57 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
356 | 59 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
515 | 63 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
131 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
146 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
117 | 27 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
321 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1168 | 183 |
| Vascepa | Icosapent Ethyl | 1061 | 130 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 906 | 150 |
| Linzess | Linaclotide | 845 | 134 |
| Losartan Potassium | Losartan Potassium | 841 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 817 | 129 |
| Metformin Hcl | Metformin Hcl | 703 | 109 |
| Omeprazole | Omeprazole | 646 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 567 | 103 |
| Myrbetriq | Mirabegron | 515 | 63 |
| Creon | Lipase/Protease/Amylase | 509 | 107 |
| Escitalopram Oxalate | Escitalopram Oxalate | 431 | 72 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 431 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 431 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 425 | 63 |
| Furosemide | Furosemide | 412 | 82 |
| Gabapentin | Gabapentin | 407 | 86 |
| Synthroid | Levothyroxine Sodium | 407 | 57 |
| Azithromycin | Azithromycin | 404 | 262 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 67 |
| Atenolol | Atenolol | 393 | 57 |
| Glimepiride | Glimepiride | 356 | 52 |
| Zenpep | Lipase/Protease/Amylase | 356 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 334 | 65 |
| Dexlansoprazole Dr | Dexlansoprazole | 330 | 50 |
| Potassium Chloride | Potassium Chloride | 330 | 53 |
| Meloxicam | Meloxicam | 322 | 105 |
| Eliquis | Apixaban | 321 | 45 |
| Breo Ellipta | Fluticasone/Vilanterol | 319 | 47 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 317 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 314 | 107 |
| Valsartan | Valsartan | 305 | 58 |
| Simvastatin | Simvastatin | 299 | 40 |
| Gemfibrozil | Gemfibrozil | 285 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 279 | 137 |
| Dexilant | Dexlansoprazole | 273 | 36 |
| Ranolazine Er | Ranolazine | 273 | 41 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 267 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 258 | 48 |
| Carvedilol | Carvedilol | 255 | 33 |
| Meclizine Hcl | Meclizine Hcl | 254 | 73 |
| Zolpidem Tartrate | Zolpidem Tartrate | 240 | 50 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 217 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 208 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 204 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 38 |
| Nifedipine Er | Nifedipine | 200 | 39 |
| Icosapent Ethyl | Icosapent Ethyl | 174 | 42 |
| Januvia | Sitagliptin Phosphate | 164 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 27 |
| Alendronate Sodium | Alendronate Sodium | 161 | 19 |
| Xarelto | Rivaroxaban | 161 | 26 |
| Montelukast Sodium | Montelukast Sodium | 160 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 41 |
| Nexium | Esomeprazole Magnesium | 146 | 25 |
| Memantine Hcl Er | Memantine Hcl | 145 | 29 |
| Labetalol Hcl | Labetalol Hcl | 144 | 18 |
| Finasteride | Finasteride | 140 | 24 |
| Lisinopril | Lisinopril | 139 | 21 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 135 | 31 |
| Farxiga | Dapagliflozin Propanediol | 131 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 130 | 16 |
| Prednisone | Prednisone | 129 | 76 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 127 | 43 |
| Jardiance | Empagliflozin | 127 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 127 | 67 |
| Dicyclomine Hcl | Dicyclomine Hcl | 125 | 50 |
| Ibuprofen | Ibuprofen | 125 | 64 |
| Symbicort | Budesonide/Formoterol Fumarate | 117 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 115 | 93 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 21 |
| Trulicity | Dulaglutide | 112 | 15 |
| Colchicine | Colchicine | 107 | 17 |
| Crestor | Rosuvastatin Calcium | 103 | 17 |
| Incruse Ellipta | Umeclidinium Bromide | 101 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 100 | 21 |
| Trazodone Hcl | Trazodone Hcl | 100 | 23 |
| Celecoxib | Celecoxib | 97 | 24 |
| Famotidine | Famotidine | 96 | 17 |
| Lidocaine | Lidocaine | 91 | 19 |
| Sertraline Hcl | Sertraline Hcl | 90 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 90 | 15 |
| Pregabalin | Pregabalin | 88 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 87 | 30 |
| Enalapril Maleate | Enalapril Maleate | 86 | 14 |
| Lorazepam | Lorazepam | 84 | 36 |
| Donepezil Hcl | Donepezil Hcl | 79 | 17 |
| Restasis | Cyclosporine | 79 | 11 |
| Levofloxacin | Levofloxacin | 75 | 52 |
| Memantine Hcl | Memantine Hcl | 72 | 18 |
| Mirtazapine | Mirtazapine | 71 | 18 |
| Spironolactone | Spironolactone | 71 | 18 |
| Allopurinol | Allopurinol | 70 | 12 |
| Clonidine Hcl | Clonidine Hcl | 69 | 19 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 68 | 11 |
| Ramipril | Ramipril | 68 | suppressed |
| Mounjaro | Tirzepatide | 65 | 13 |
| Jentadueto | Linagliptin/Metformin Hcl | 64 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 63 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | suppressed |
| Cilostazol | Cilostazol | 62 | 11 |
| Procto-Med Hc | Hydrocortisone | 58 | 23 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 56 | suppressed |
| Ezetimibe | Ezetimibe | 55 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | suppressed |
| Repatha Sureclick | Evolocumab | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 43 |
| Spiriva Handihaler | Tiotropium Bromide | 50 | suppressed |
| Benicar | Olmesartan Medoxomil | 49 | suppressed |
| Diovan | Valsartan | 49 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 47 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 47 | 26 |
| Irbesartan | Irbesartan | 46 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | 21 |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 45 | suppressed |
| Livalo | Pitavastatin Calcium | 45 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 44 | suppressed |
| Hydrocortisone | Hydrocortisone | 43 | 18 |
| Ozempic | Semaglutide | 43 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 42 | 12 |
| Metronidazole | Metronidazole | 41 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Repaglinide | Repaglinide | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 39 | suppressed |
| Clonazepam | Clonazepam | 39 | 14 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 38 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 38 | suppressed |
| Multaq | Dronedarone Hcl | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 36 | 19 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 35 | 13 |
| Trulance | Plecanatide | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 31 | suppressed |
| Cozaar | Losartan Potassium | 31 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Methimazole | Methimazole | 31 | suppressed |
| Bystolic | Nebivolol Hcl | 30 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 30 | suppressed |
| Hyzaar | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Nystatin | Nystatin | 29 | 12 |
| Toprol Xl | Metoprolol Succinate | 29 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | 13 |
| Ammonium Lactate | Ammonium Lactate | 26 | 15 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Rapaflo | Silodosin | 26 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 26 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 19 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 24 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Clotrimazole | Clotrimazole | 23 | 13 |
| Edarbi | Azilsartan Medoxomil | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Naproxen | Naproxen | 22 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Lexapro | Escitalopram Oxalate | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Micardis | Telmisartan | 19 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 19 | suppressed |
| Proctozone-Hc | Hydrocortisone | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Namenda Xr | Memantine Hcl | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 15 | suppressed |
| Plavix | Clopidogrel Bisulfate | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Lipitor | Atorvastatin Calcium | 14 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Tribenzor | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Xeljanz | Tofacitinib Citrate | 13 | suppressed |
| Avodart | Dutasteride | 12 | suppressed |
| Climara Pro | Estradiol/Levonorgestrel | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Horizant | Gabapentin Enacarbil | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Norvasc | Amlodipine Besylate | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Altace | Ramipril | 11 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Jublia | Efinaconazole | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,174.33 · 129 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AIRSUPRA, APLENZIN, ARISTADA, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, COBENFY, CREON, FANAPT, FARXIGA, GEMTESA, INGREZZA, Korlym, LINZESS, LYBALVI, OTEZLA, Ozempic, REPATHA, REXULTI, SPRAVATO, TRELEGY ELLIPTA, TRINTELLIX, UZEDY, VOQUEZNA, VRAYLAR, Veozah, WAKIX, YUPELRI, ZENPEP | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error